Three Hundred Eighty Tablets Short: Loss Reporting at a Topeka Independent
Priya, pharmacist-in-charge of a 1,400-square-foot independent pharmacy in Topeka, is completing the biennial controlled substance inventory required by DEA. The pharmacist who ran the last count left in January, and the store has used three different floater pharmacists since. Her count shows 620 tablets of oxycodone 15 mg on hand against a book balance of 1,000, and 40 alprazolam 1 mg tablets missing against a book balance of 300. Separately, a receiving technician signed for a wholesaler shipment of ten cases last month but wrote "received 9 of 10" in the invoice margin; no one followed up. Priya also finds a DEA Form 222 pad in an unlocked desk drawer and two controlled substance invoices that were never signed or dated. Nothing suggests patient harm. She has until Friday to decide what to do and worries that reporting will trigger an inspection.
1. What must Priya report, to whom, on what form, and on what timeline?
Read the worked answer
A 380-tablet oxycodone gap is not a rounding error. It is a significant loss, and DEA requires a registrant that cannot account for controlled substances to report rather than absorb the discrepancy.
- DEA Form 106, Report of Theft or Loss. File with the DEA field office in writing within one business day of discovery. One form can cover the event; list both oxycodone and alprazolam, the quantities, and the known circumstances. Retain a copy as a record.
- Local law enforcement. The same regulation requires notification of the appropriate local police agency.
- State board. Check the Kansas Board of Pharmacy's reporting rule for theft or significant loss; state notice obligations sit on top of the federal filing.
Do not wait for an internal investigation to conclude, and never adjust the books to make the gap disappear. A Form 106 can be supplemented as facts develop; a missed filing cannot be undone and is itself a violation. Because employee diversion is a real possibility, involve counsel and human resources - but the regulatory clock runs independently of any internal inquiry.
2. How should the short wholesaler shipment have been handled, and does it change the Form 106 obligation?
Read the worked answer
In-transit losses are treated differently from on-hand losses. Under DEA rules, when controlled substances are lost in transit, the supplier - the registrant that shipped them - is the party that reports the loss on Form 106. The receiving pharmacy's obligation is to document the shortage at the point of receipt, notify the supplier immediately, and keep that paper trail. The technician's margin note was a start, but it needed a dated receiving-discrepancy report, a signature, and same-day written notice to the wholesaler.
What the pharmacy cannot do is let the shortage blend into its own book balance. The 380-tablet oxycodone gap and the 40-tablet alprazolam gap measure what the pharmacy recorded as received against what it has on hand, and unless reconciliation proves otherwise, that is an on-hand loss belonging in Priya's own Form 106. Accurate reconciliation of receipts, dispensing records, returns, and dispensing-by-prescription reports may show that some portion never arrived, in which case that portion belongs to the supplier's report. Either way, file promptly and amend if the reconciliation shifts the numbers.
3. What recordkeeping and control failures must be fixed before an inspection?
Read the worked answer
The inventory and receiving failures are the ones an inspector will cite, and each has a specific fix.
- Form 222 security. DEA-222 forms must be secured and accessible only to authorized personnel; a pad in an unlocked drawer is a finding. Assign an owner and maintain a 222 log, including any powers of attorney.
- Signatures and dates. Controlled substance invoices must be signed and dated by the person receiving them, showing the date received. Two unsigned invoices are incomplete records.
- Biennial inventory. Schedule II counts must be exact, dated when taken, and retained for two years. Three different floaters running the pharmacy argues for a written count procedure and one accountable person.
- Records retention and separation. Schedule II records must be maintained separately from all other records, and all controlled substance records kept for two years and available for inspection.
- Access controls. Review who can open the CII safe, and institute perpetual counts with a second-person verification so a future discrepancy surfaces in days rather than at the next biennial.